Abstract
Hydroxyapatite crystals are often deposited in the vicinity of joints, where they can cause a clinical periarthritis. Clodronate is a first-generation bisphosphonate that has the ability to reduce ectopic calcifications. Two women were affected by disabling calcific periarthritis of the shoulders lasting for years and resistant to any traditional drug (including glucocorticoids), infiltration and surgical treatment. We treated both patients with low-dose methylprednisolone added to intramuscular clodronate at the daily dose of 100 mg administered for 20 days every 3 months for 5 cycles (18 months). In both cases, the results were clinically evident within 1 month, showing a significant reduction in pain and disability. After 18 months, the result was furthermore radiologically evident in both cases with a great reduction in the size of calcifications. These improvements were still present at follow-up after 7 and 5 years with complete functional recovery.
Abbreviations
- HA:
-
Hydroxyapatite
- CLO:
-
Clodronate
- BP:
-
Bisphosphonate
- HADD:
-
Hydroxyapatite crystal-deposition disease
- GC:
-
Glucocorticoids
- MP:
-
6-Methylprednisolone
- im:
-
Intramuscular
- iv:
-
Intravenous
References
Dieppe PA, Crocker P, Huskisson EC, Willoughby DA (1976) Apatite deposition disease. A new arthropathy. Lancet 1:266–269
Bonavita JA, Dalinka MK, Schumacher HR Jr (1980) Hydroxyapatite deposition disease. Radiology 134:621–625
McCarty GM (1998) Crystal related arthropathies. In: Klippel JH, Dieppe PA (eds) Rheumatology, 2nd edn. Mosby, London (section 8)
Garcia GM, McCord GC, Kumar R (2003) Hydroxyapatite crystal deposition disease. Seminar Musculoskelet Radiol 7:187–193
Pfister J, Gerber H (1997) Chronic calcifying tendinitis of the shoulder-therapy by percutaneous needle aspiration and lavage: a prospective open study of 62 shoulders. Clin Rheumatol 16:269–274
Fleisch H (1998) Bisphosphonates: mechanism of action. Endocr Rev 19:80–100
Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W et al (2006) Novel insight into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627
Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14:1–7
Ylitalo R, Syvala H, Touhimaa P, Ylitalo P (2002) Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol 90:139–143
Fujii N, Hamano T, Isaka Y, Ito T, Imai E (2005) Risedronate: a possible treatment for extraosseous calcification. Clin Calcium 15:S1 75–S1 78
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saviola, G., Abdi-Ali, L., Baiardi, P. et al. Can clodronate be effective in the treatment of disabling hydroxyapatite crystal-deposition disease? A report of two cases. Rheumatol Int 31, 415–417 (2011). https://doi.org/10.1007/s00296-010-1575-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-010-1575-2